Terms & Properties

Preferred Name:  Lisocabtagene Maraleucel

Definition:  A preparation of a defined ratio of CD4+ and CD8+ autologous T-lymphocytes transduced with a lentiviral vector expressing a chimeric antigen receptor (CAR) containing an anti-CD19 single chain variable fragment (scFv) fused to the signaling domain of 4-1BB (CD137), the zeta chain of the TCR/CD3 complex (CD3-zeta), and a truncated form of the human epidermal growth factor receptor (EGFRt), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, lisocabtagene maraleucel is directed to and induces selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. Devoid of both ligand binding domains and tyrosine kinase activity, the expressed EGFRt both facilitates in vivo detection of the administered, transduced T-cells and can promote elimination of those cells through a cetuximab-induced antibody dependent cellular cytotoxicity (ADCC) response. The 4-1BB costimulatory signaling domain enhances both proliferation of T-cells and antitumor activity.

Display Name:  Lisocabtagene Maraleucel

Label:  Lisocabtagene Maraleucel

NCI Thesaurus Code:  C125192 (Search for linked caDSR metadata)   (search value sets)

NCI Metathesaurus Link:  CL504006  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)

Anti-CD19-CAR Genetically Engineered Autologous T Lymphocytes JCAR017

Anti-CD19-CAR Genetically Engineered Autologous T-lymphocytes JCAR017

Autologous Anti-CD19-EGFRt-4-1BB-zeta-modified CAR CD8+ and CD4+ T-lymphocytes JCAR017

Breyanzi

JCAR 017

JCAR-017

JCAR017

Liso-cel

Lisocabtagene Maraleucel

LISOCABTAGENE MARALEUCEL

Lisocabtagene maraleucel

External Source Codes: 

NCI Drug Dictionary ID	778386 (see NCI Drug Dictionary info)
FDA UNII Code	7K2YOJ14X0
PDQ Closed Trial Search ID	778386
PDQ Open Trial Search ID	778386
NCI META CUI	CL504006

Other Properties:

Name	Value (qualifiers indented underneath)
Accepted_Therapeutic_Use_For	adult patients with certain types of large B-cell lymphoma
code	C125192
Contributing_Source	CTRP
Contributing_Source	FDA
Contributing_Source	GDC
Contributing_Source	HemOnc
Maps_To	Lisocabtagene Maraleucel
	Target_Terminology: GDC       Relationship_to_Target: Has Synonym       Target_Term_Type: PT       Target_Code: therapeutic_agents
Semantic_Type	Cell
Semantic_Type	Pharmacologic Substance

Additional Concept Data: 

Defined Fully by Roles: No

URL:https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C125192